2004
HPA axis activation in major depression and response to fluoxetine: a pilot study
Young E, Altemus M, Lopez J, Kocsis J, Schatzberg A, deBattista C, Zubieta J. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 2004, 29: 1198-1204. PMID: 15219644, DOI: 10.1016/j.psyneuen.2004.02.002.Peer-Reviewed Original ResearchConceptsHPA axis activationMetyrapone challengeOnset of treatmentAxis activationMajor depressionHPA axisHamilton Depression Rating Scale ratingsOpen-label treatmentHPA axis dysregulationAdrenal axis activationPremenopausal womenLabel treatmentACTH levelsHormonal contraceptivesMedical illnessACTH secretionAxis dysregulationNormal womenDepressed patientsFluoxetine respondersDepressed womenNormal subjectsAxis IGreater severityFluoxetine
1998
Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients
Greenberg B, Benjamin J, Martin J, Keuler D, Huang S, Altemus M, Murphy D. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology 1998, 140: 434-444. PMID: 9888619, DOI: 10.1007/s002130050787.Peer-Reviewed Original ResearchConceptsFluoxetine-treated patientsObsessive-compulsive disorderUnmedicated patientsAdministration of metergolineSerotonin reuptake inhibitorsUnderlie symptomsUntreated patientsBrain serotoninReuptake inhibitorsSerotonin antagonistsSerotonergic transmissionSingle doseSymptom exacerbationReceptor responsivityTherapeutic effectMetergolinePatientsPlaceboSymptom ratingsSymptomsSuch treatmentSerotoninDisordersPilot resultsDays
1996
Effects of serotonergic agents on food-restriction-induced hyperactivity
Altemus M, Glowa J, Galliven E, Leong Y, Murphy D. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacology Biochemistry And Behavior 1996, 53: 123-131. PMID: 8848441, DOI: 10.1016/0091-3057(95)02003-9.Peer-Reviewed Original ResearchConceptsSaline-treated ratsObsessive-compulsive disorderReuptake inhibitorsSerotonin selective reuptake inhibitorsSelective monoamine reuptake inhibitorsSelective reuptake inhibitorsChronic fluoxetine treatmentMonoamine reuptake inhibitorsTryptophan hydroxylase inhibitorCentral serotonergic activityPossible animal modelOCD symptomsFluoxetine treatmentChronic treatmentPharmacological treatmentSerotonergic agentsSerotonergic neurotransmissionSerotonergic activityFood restrictionHydroxylase inhibitorAnimal modelsRunning wheelRatsParachlorophenylalanineAdditional group
1993
Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
De Bellis M, Geracioti T, Altemus M, Kling M. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry 1993, 33: 636-641. PMID: 7687151, DOI: 10.1016/0006-3223(93)90103-k.Peer-Reviewed Original ResearchConceptsMedication-free patientsHealthy volunteersFluoxetine treatmentHomovanillic acidMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresDepression Rating Scale scoresPmol/CSF monoamine metabolite levelsFluoxetine-treated patientsCerebrospinal fluid levelsMajor depressive disorderMonoamine metabolite levelsRating Scale scoresCerebrospinal fluid monoamineHVA/5-HIAA ratioCSF HVA/5-HIAA ratioDepressive disorderMajor depressionScale scoreFluid levelsPatientsDSM-IIIMetabolite levelsVolunteersAttenuation of food-restriction-induced running by chronic fluoxetine treatment.
Altemus M, Glowa J, Murphy D. Attenuation of food-restriction-induced running by chronic fluoxetine treatment. Psychopharmacology Bulletin 1993, 29: 397-400. PMID: 8121967.Peer-Reviewed Original ResearchConceptsSaline-treated controlsObsessive-compulsive disorderAnimal modelsRunning wheelChronic fluoxetine treatmentPossible animal modelValid animal modelLife-threatening proportionsOCD symptomsAssociated anorexiaFluoxetine treatmentFood restrictionBody weightRatsAntidepressantsWeight lossSignificant attenuationCompulsive runningProgressive increaseAnorexiaFluoxetineDaily accessSymptomsWeeksTreatment
1992
Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro
Altemus M, Cizza G, Gold P. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Research 1992, 593: 311-313. PMID: 1450938, DOI: 10.1016/0006-8993(92)91326-a.Peer-Reviewed Original Research